Background: Natural killer cells (NK) and innate lymphoid cells with their subsets (ILC) are part of the innate immune system.

Objective: The aim is to evaluate how NK cells and ILC cells interact in atopic dermatitis (AD) patients (with and without dupilumab therapy) compared to control group.

Materials And Methods: Complete dermatological examination was performed in all patients included in the study (19 AD patients with dupilumab, 17 AD patients without dupilumab). Surface molecules expressed on NK cells and ILC cells were analyzed by flow cytometry. The association between NK cells and total ILC cells, ILC-1, ILC-2, ILC-3, NCR+ILC3, NCRILC3 were compared in AD patients and in the control group. The non-parametric Spearman's rank correlation coefficient was used for this statistical analysis. We evaluated the association of parameters with AD severity at the time of treatment.Non-parametric Mann-Whitney, Kolmogorov-Smirnov tests were used.

Results: We confirmed the higher association between NK cells and total ILC cells in AD patients without dupilumab therapy (in 30.3 %) and in healthy controls (in 27.2 %); this association is low in AD patients with dupilumab therapy (in 0.1 %). The higher association was confirmed between NK cells and ILCs subsets only in AD patients without dupilumab therapy; in these patients the highest association was confirmed between NK cells and ILC-2 cells (in 38.6 %). No statistically significant difference in the count of NK cells and ILC cells was found between mild and moderate form of AD patients treated with dupilumab.

Conclusion: Targeting these cell types or the cytokines they produce could represent potential therapeutic strategies for controlling inflammation and alleviating symptoms in AD patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2024.112327DOI Listing

Publication Analysis

Top Keywords

patients dupilumab
28
ilc cells
24
dupilumab therapy
20
cells ilc
16
cells
16
patients
12
cells subsets
8
atopic dermatitis
8
dermatitis patients
8
association cells
8

Similar Publications

Background: Inhibition of IL-4/IL-13 driven inflammation by dupilumab has shown significant clinical benefits in treatment of atopic dermatitis (AD).

Objective: To assess longitudinal protein and metabolite composition in AD skin during dupilumab treatment.

Methods: Skin tape strip (STS) were collected from lesional/non-lesional skin of 20 AD patients during 16-week dupilumab treatment and from 20 healthy volunteers (HV) followed for 16-weeks.

View Article and Find Full Text PDF

Introduction: We assessed potential mechanisms behind the requirement for more frequent dupilumab dosing in eosinophilic esophagitis (EoE) compared with other approved indications.

Methods: Results for the phase 3 LIBERTY EoE TREET study coprimary endpoints (proportion of patients achieving a peak intraepithelial eosinophil count of ≤6 eosinophils per high-power field and absolute change from baseline in Dysphagia Symptom Questionnaire total score) were pooled in exposure-response analyses.

Results: A steep initial relationship then plateau was observed between higher dupilumab steady-state trough concentrations and decreased eosinophilic infiltration at week 24, whereas a graded exposure-response relationship was observed for symptomatic improvement at week 24.

View Article and Find Full Text PDF

Higher Odds of Dupilumab Prescriptions for Black Patients with Atopic Dermatitis: Results of a Retrospective Study Using DataDerm, The Database of The American Academy of Dermatology.

J Am Acad Dermatol

January 2025

Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA; Dermatology Service, US Department of Veterans Affairs, Eastern Colorado Health Care System, Aurora, CO, USA; Department of Dermatology, University of Minnesota School of Medicine, Minneapolis, MN, USA. Electronic address:

View Article and Find Full Text PDF

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the nasal passages and sinuses, often characterized by nasal congestion, loss of smell, facial pressure, and nasal discharge. Conventional treatments, such as corticosteroids and endoscopic sinus surgery (ESS), often provide only temporary relief, with frequent recurrence of symptoms. For patients with severe, refractory CRSwNP, biologic therapies have emerged as a promising treatment option.

View Article and Find Full Text PDF

Olfactory impairment in Italian patients with chronic rhinosinusitis with nasal polyps: a patient-centered survey.

Front Allergy

January 2025

Unit of Otorhinolaryngology-Head and Neck Department, ASST Sette Laghi, Varese and UPLOAD (Upper and Lower Airways Diseases) Research Centre, University of Insubria, Varese, Italy.

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition characterized by persistent nasal obstruction, discharge, facial pressure, and olfactory dysfunction. CRSwNP significantly impairs quality of life (QoL), with olfactory loss being a particularly distressing symptom that affects food enjoyment, personal safety, and social interactions.

Methods: This study investigated the experiences of Italian patients with CRSwNP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!